Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p194
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 194/312)
Character Range: 16694539–16703393

for this patient.
C15688              P15688         PN15688          Macrogol 3350                                                          Constipation
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must be receiving palliative care.
C15691              P15691         CN15691          Aclidinium with formoterol                                             Chronic obstructive pulmonary disease (COPD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 15691
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Indacaterol with glycopyrronium                                        Patient must have COPD symptoms that persist despite regular bronchodilator treatment with a long acting muscarinic antagonist (LAMA); OR
                                                                                                                           Patient must have COPD symptoms that persist despite regular bronchodilator treatment with a long acting beta 2 agonist (LABA); OR
                                                    Tiotropium with olodaterol                                             Patient must have been stabilised on a combination of a LAMA and a LABA.

                                                    Umeclidinium with vilanterol

C15692              P15692         CN15692          Fluticasone furoate with vilanterol                                    Asthma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 15692
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids.
                                                                                                                           Patient must be aged 12 years or over.
C15693              P15693         CN15693          Fluticasone propionate with salmeterol                                 Asthma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 15693
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids.
C15696              P15696         CN15696          Escitalopram                                                           Moderate to severe social anxiety disorder (social phobia, SAD)
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
                                                                                                                           Patient must not have responded to non-pharmacological therapy; AND
                                                                                                                           Patient must have been assessed by a psychiatrist.
C15698              P15698         CN15698          Escitalopram                                                           Moderate to severe social anxiety disorder (social phobia, SAD)
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
                                                                                                                           Patient must not have responded to non-pharmacological therapy; AND
                                                                                                                           Patient must have been assessed by a psychiatrist.
C15699              P15699         CN15699          Safinamide                                                             Parkinson disease
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The treatment must be as adjunctive therapy to a levodopa-decarboxylase